| UHC Medicaid Medical & Drug | Cell-Free Fetal DNA Testing – Community Plan Medical Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | Continuous Glucose Monitoring and Insulin Delivery for Managing Diabetes – Community Plan Medical Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | Encelto® (Revakinagene Taroretcel-Lwey) – Community Plan Medical Benefit Drug Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | Entyvio® (Vedolizumab) – Community Plan Medical Benefit Drug Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | FDA Cleared or Approved Companion Diagnostic Testing – Community Plan Medical Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | Genetic Testing for Hereditary Cancer – Community Plan Medical Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | Habilitation and Rehabilitation Therapy (Occupational, Physical, and Speech) (for Florida Only) – Community Plan Medical Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | Habilitation and Rehabilitation Therapy (Occupational, Physical, and Speech) – Community Plan Medical Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | Intracanalicular and Intravitreal Corticosteroid Implants – Community Plan Medical Benefit Drug Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | Lower Extremity Prosthetics – Community Plan Medical Policy | 2026-08-01 |